$PTCT
PTC THERAPEUTICS, INC. Stock $ptct

$ptct Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-K Financial Statement

#000107008119000018 Filed on March 01, 2019

Income Statement

Concept	2019 Q1	2018 Q4	2018
Revenue	$53.58M	$85.83M	$264.7M
YoY Change	-4.42%	48.11%	36.19%
Cost Of Revenue	$2.376M	$3.800M	$12.67M
YoY Change	-21.97%	58.33%	176.82%
Gross Profit	$51.21M	$82.60M	$252.1M
YoY Change	-3.41%	9.26%	32.79%
Gross Profit Margin	95.57%	96.23%	95.21%
Selling, General & Admin	$40.54M	$48.70M	$153.5M
YoY Change	22.98%	37.18%	26.62%
% of Gross Profit	79.18%	58.96%	60.92%
Research & Development	$52.57M	$53.60M	$172.0M
YoY Change	67.61%	83.56%	46.42%
% of Gross Profit	102.65%	64.89%	68.23%
Depreciation & Amortization	$7.059M	$6.770M	$26.09M
YoY Change	17.22%	13.97%	47.53%
% of Gross Profit	13.79%	8.2%	10.35%
Operating Expenses	$122.7M	$131.5M	$380.4M
YoY Change	68.56%	81.15%	47.06%
Operating Profit	-$69.14M	-$45.14M	-$115.7M
YoY Change	312.95%	-927.92%	79.94%
Interest Expense	-$2.288M	-$3.200M	-$12.55M
YoY Change	-30.73%	-5.88%	3.8%
% of Operating Profit
Other Income/Expense, Net	-$109.0K	-$900.0K	$129.0K
YoY Change	-110.86%	-1000.0%	-110.09%
Pretax Income	-$71.54M	-$49.30M	-$128.1M
YoY Change	275.68%	-2447.62%	64.95%
Income Tax	$576.0K	-$1.000M	-$29.00K
% Of Pretax Income
Net Earnings	-$72.11M	-$48.33M	-$128.1M
YoY Change	274.36%	-3905.51%	62.13%
Net Earnings / Revenue	-134.58%	-56.31%	-48.38%
Basic Earnings Per Share			-$2.75
Diluted Earnings Per Share	-$1.290M	-$958.3K	-$2.749M
COMMON SHARES
Basic Shares Outstanding	58.40M shares	50.45M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2018 Q4	2018
SHORT-TERM ASSETS
Cash & Short-Term Investments	$407.2M	$227.6M	$227.6M
YoY Change	128.38%	19.04%	19.04%
Cash & Equivalents	$201.1M	$169.5M	$169.5M
Short-Term Investments	$206.0M	$58.10M	$58.10M
Other Short-Term Assets	$9.300M	$9.200M	$9.200M
YoY Change	60.34%	37.31%	37.31%
Inventory	$16.22M	$16.12M	$16.10M
Prepaid Expenses
Receivables	$46.40M	$67.90M	$67.90M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$479.1M	$320.9M	$320.9M
YoY Change	97.97%	28.83%	28.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.54M	$12.69M	$12.70M
YoY Change	75.14%	51.55%	51.19%
Goodwill	$82.34M	$82.34M
YoY Change
Intangibles	$695.0M	$701.0M
YoY Change	444.79%	427.12%
Long-Term Investments
YoY Change
Other Assets	$2.300M	$2.300M	$2.300M
YoY Change	53.33%	91.67%	91.67%
Total Long-Term Assets	$804.8M	$798.4M	$798.3M
YoY Change	485.69%	459.9%	459.82%
TOTAL ASSETS
Total Short-Term Assets	$479.1M	$320.9M	$320.9M
Total Long-Term Assets	$804.8M	$798.4M	$798.3M
Total Assets	$1.284B	$1.119B	$1.119B
YoY Change	238.4%	185.77%	185.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.786M	$6.001M	$6.000M
YoY Change	215.27%	-60.73%	-60.78%
Accrued Expenses	$24.00M	$27.60M	$27.60M
YoY Change	160.87%	55.93%	55.93%
Deferred Revenue	$5.497M	$3.716M
YoY Change		-5.61%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$16.67M	$11.67M	$11.70M
YoY Change
Total Short-Term Liabilities	$143.0M	$166.8M	$166.8M
YoY Change	96.72%	103.29%	103.41%
LONG-TERM LIABILITIES
Long-Term Debt	$138.5M	$141.3M	$141.3M
YoY Change	-5.73%	-2.5%	-2.55%
Other Long-Term Liabilities	$8.770M	$58.00K	$338.3M
YoY Change	4096.17%	-76.13%	4025.61%
Total Long-Term Liabilities	$147.2M	$141.4M	$479.6M
YoY Change	0.1%	-2.62%	213.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$143.0M	$166.8M	$166.8M
Total Long-Term Liabilities	$147.2M	$141.4M	$479.6M
Total Liabilities	$771.0M	$768.5M	$768.5M
YoY Change	236.52%	226.72%	226.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.011B	-$938.9M
YoY Change	21.79%	15.33%
Common Stock	$58.00K	$51.00K
YoY Change	38.1%	21.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$512.9M	$350.7M	$350.7M
YoY Change
Total Liabilities & Shareholders Equity	$1.284B	$1.119B	$1.119B
YoY Change	238.4%	185.77%	185.73%

Cashflow Statement

Concept	2019 Q1	2018 Q4	2018
OPERATING ACTIVITIES
Net Income	-$72.11M	-$48.33M	-$128.1M
YoY Change	274.36%	-3905.51%	62.13%
Depreciation, Depletion And Amortization	$7.059M	$6.770M	$26.09M
YoY Change	17.22%	13.97%	47.53%
Cash From Operating Activities	-$42.41M	-$15.14M	-$27.64M
YoY Change	167.09%	-171.11%	174.68%
INVESTING ACTIVITIES
Capital Expenditures	$2.865M	-$4.610M	$7.097M
YoY Change	498.12%	125.98%	128.86%
Acquisitions			$48.89M
YoY Change
Other Investing Activities	-$147.6M	-$19.99M	-$35.52M
YoY Change	12517.95%	-61.56%	-318.99%
Cash From Investing Activities	-$150.5M	-$24.59M	-$42.61M
YoY Change	9032.16%	-54.5%	-424.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$224.4M		$117.9M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$225.7M	3.720M	131.6M
YoY Change	19769.89%	101.08%	197.55%
NET CHANGE
Cash From Operating Activities	-$42.41M	-15.14M	-27.64M
Cash From Investing Activities	-$150.5M	-24.59M	-42.61M
Cash From Financing Activities	$225.7M	3.720M	131.6M
Net Change In Cash	$31.65M	-36.01M	57.71M
YoY Change	-293.08%	16.54%	7.92%
FREE CASH FLOW
Cash From Operating Activities	-$42.41M	-$15.14M	-$27.64M
Capital Expenditures	$2.865M	-$4.610M	$7.097M
Free Cash Flow	-$45.27M	-$10.53M	-$34.74M
YoY Change	176.79%	-145.14%	163.89%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001070081
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	58401698	shares
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	1521120427	USD
CY2018	dei	Entity Registrant Name EntityRegistrantName	PTC THERAPEUTICS, INC.
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	false
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2017Q4	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	5137000	USD
CY2018Q4	ptct	Accrued Consulting And Contracted Research Current AccruedConsultingAndContractedResearchCurrent	11267000	USD
CY2018	ptct	Adjustmentsto Additional Paid In Capital Receivablefrom Investor AdjustmentstoAdditionalPaidInCapitalReceivablefromInvestor	929000	USD
CY2017Q4	ptct	Available For Sale Securities Debt Maturities Over One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue	10077000	USD
CY2018Q4	ptct	Available For Sale Securities Debt Maturities Over One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue	0	USD
CY2017Q4	ptct	Business Combination Consideration Liability Deferred Consideration Payable Current BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent	0	USD
CY2018Q4	ptct	Business Combination Consideration Liability Deferred Consideration Payable Current BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableCurrent	19400000	USD
CY2017Q4	ptct	Business Combination Consideration Liability Deferred Consideration Payable Long Term BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableLongTerm	0	USD
CY2018Q4	ptct	Business Combination Consideration Liability Deferred Consideration Payable Long Term BusinessCombinationConsiderationLiabilityDeferredConsiderationPayableLongTerm	18300000	USD
CY2016	ptct	Change In Unrealized Gain Loss On Marketable Securities ChangeInUnrealizedGainLossOnMarketableSecurities	386000	USD
CY2017	ptct	Change In Unrealized Gain Loss On Marketable Securities ChangeInUnrealizedGainLossOnMarketableSecurities	225000	USD
CY2018	ptct	Change In Unrealized Gain Loss On Marketable Securities ChangeInUnrealizedGainLossOnMarketableSecurities	9000	USD
CY2017Q1	ptct	Collaboration And Grant Revenue CollaborationAndGrantRevenue	105000	USD
CY2017Q2	ptct	Collaboration And Grant Revenue CollaborationAndGrantRevenue	71000	USD
CY2017Q3	ptct	Collaboration And Grant Revenue CollaborationAndGrantRevenue	73000	USD
CY2017Q4	ptct	Collaboration And Grant Revenue CollaborationAndGrantRevenue	20077000	USD
CY2018Q1	ptct	Collaboration And Grant Revenue CollaborationAndGrantRevenue	81000	USD
CY2018Q2	ptct	Collaboration And Grant Revenue CollaborationAndGrantRevenue	573000	USD
CY2018Q3	ptct	Collaboration And Grant Revenue CollaborationAndGrantRevenue	570000	USD
CY2018Q4	ptct	Collaboration And Grant Revenue CollaborationAndGrantRevenue	505000	USD
CY2018	ptct	Contract With Customer Liability Amounts Recognized Beginning Of Measurement Period ContractWithCustomerLiabilityAmountsRecognizedBeginningOfMeasurementPeriod	0	USD
CY2018	ptct	Contract With Customer Liability Increase From Cash Receipts ContractWithCustomerLiabilityIncreaseFromCashReceipts	6417000	USD
CY2017Q4	ptct	Deferred Research And Development Costs DeferredResearchAndDevelopmentCosts	500000	USD
CY2018Q4	ptct	Deferred Research And Development Costs DeferredResearchAndDevelopmentCosts	2400000	USD
CY2017Q4	ptct	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	2116000	USD
CY2018Q4	ptct	Deferred Tax Assets Amortization DeferredTaxAssetsAmortization	5148000	USD
CY2017Q4	ptct	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	3332000	USD
CY2018Q4	ptct	Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts	2093000	USD
CY2018Q4	ptct	Deferred Tax Assets Operating Loss Carryforwards Limitedby Irc Section382 DeferredTaxAssetsOperatingLossCarryforwardsLimitedbyIRCSection382	231500000	USD
CY2017Q4	ptct	Deferred Tax Assets Tax Credit Federal DeferredTaxAssetsTaxCreditFederal	80961000	USD
CY2018Q4	ptct	Deferred Tax Assets Tax Credit Federal DeferredTaxAssetsTaxCreditFederal	89070000	USD
CY2017Q4	ptct	Deferred Tax Assets Tax Credit State DeferredTaxAssetsTaxCreditState	7148000	USD
CY2018Q4	ptct	Deferred Tax Assets Tax Credit State DeferredTaxAssetsTaxCreditState	5473000	USD
CY2017Q4	ptct	Deferred Tax Liabilities Convertible Debt DeferredTaxLiabilitiesConvertibleDebt	9927000	USD
CY2018Q4	ptct	Deferred Tax Liabilities Convertible Debt DeferredTaxLiabilitiesConvertibleDebt	7353000	USD
CY2017Q4	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	1221000	USD
CY2018Q4	ptct	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	2299000	USD
CY2016	ptct	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0370
CY2017	ptct	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0848
CY2018	ptct	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	0.0641
CY2016	ptct	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Transition Tax On Accumulated Foreign Earnings Percent EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017TransitionTaxOnAccumulatedForeignEarningsPercent	0.0000
CY2017	ptct	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Transition Tax On Accumulated Foreign Earnings Percent EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017TransitionTaxOnAccumulatedForeignEarningsPercent	-0.6412
CY2018	ptct	Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Transition Tax On Accumulated Foreign Earnings Percent EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017TransitionTaxOnAccumulatedForeignEarningsPercent	-0.1422
CY2018Q4	ptct	Lessee Operating Lease Liability Payments Due Year Fiveand Thereafter LesseeOperatingLeaseLiabilityPaymentsDueYearFiveandThereafter	3321000	USD
CY2014Q3	ptct	Minimum Age Of Ambulatory Patient MinimumAgeOfAmbulatoryPatient	P5Y
CY2018	ptct	Net Product Sales NetProductSales	263005000	USD
CY2018Q4	ptct	Numberof Operating Leases NumberofOperatingLeases	3	operating_lease
CY2018	ptct	Operating Loss Carryforwards For Immediate Use OperatingLossCarryforwardsForImmediateUse	194500000	USD
CY2018	ptct	Operating Loss Carryforwards In Next Twelve Months OperatingLossCarryforwardsInNextTwelveMonths	5700000	USD
CY2018	ptct	Renewal Of Marketing Authorization Period RenewalOfMarketingAuthorizationPeriod	P1Y
CY2017Q4	ptct	Sales Allowance And Other Related Costs SalesAllowanceAndOtherRelatedCosts	22257000	USD
CY2018Q4	ptct	Sales Allowance And Other Related Costs SalesAllowanceAndOtherRelatedCosts	29417000	USD
CY2017Q4	ptct	Sales Rebates And Royalties Current SalesRebatesAndRoyaltiesCurrent	11657000	USD
CY2018Q4	ptct	Sales Rebates And Royalties Current SalesRebatesAndRoyaltiesCurrent	31874000	USD
CY2018	ptct	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit	46100000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	76446000	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	128199000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	15282000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6001000	USD
CY2016	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1885000	USD
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-535000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	433000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2116000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5574000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	32844000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7483000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	3969000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1462000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	966534000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1288137000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	35009000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	30559000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	33252000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35009000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	30559000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	33252000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	800000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	700000	USD
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	302000	USD
CY2017	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	433000	USD
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	524000	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15380000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22877000	USD
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6125967	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6841653	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9105837	shares
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017Q4	us-gaap	Assets Assets	391653000	USD
CY2018Q4	us-gaap	Assets Assets	1119222000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	249063000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	320857000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	30000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	79432000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	58056000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	52000	USD
CY2018Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	43000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	69377000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	58088000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	79454000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	58088000	USD
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	0	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	0	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1	-19340000	USD
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	0	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	19340000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	310240000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58022000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58321000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	111792000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	169498000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	299000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	53471000	USD
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	57706000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41612395	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	50606147	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41612395	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	50606147	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	42000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	51000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-142395000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-73546000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-130588000	USD
CY2017Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	11891000	USD
CY2018Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	12938000	USD
CY2018	us-gaap	Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized	1433000	USD
CY2018	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress	-3937000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3937000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3716000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	7954000	USD
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	9722000	USD
CY2018	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	USD
CY2016	us-gaap	Cost Of Goods Sold Excluding Depreciation Depletion And Amortization CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization	0	USD
CY2017	us-gaap	Cost Of Goods Sold Excluding Depreciation Depletion And Amortization CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization	4577000	USD
CY2018	us-gaap	Cost Of Goods Sold Excluding Depreciation Depletion And Amortization CostOfGoodsSoldExcludingDepreciationDepletionAndAmortization	12670000	USD
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	3266000	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	766000	USD
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1131000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	669000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	38000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	10087000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	3000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	16223000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	8000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	26310000	USD
CY2018Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	11000	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-199000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	198000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-736000	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-199000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	199000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	10067000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	129385000	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	187698000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	188570000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10067000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8089000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	231500000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	61068000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	62159000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Foreign DeferredTaxAssetsOperatingLossCarryforwardsForeign	736000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	169200000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	11884000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	165000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	62300000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	18815000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	21411000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1749000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1601000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards General Business DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness	74000000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	625000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	714000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	177600000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	177631000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	180481000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	180500000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	121296000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	0	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	122032000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	122032000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	140000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0	USD
CY2016	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1100000	USD
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1600000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2200000	USD
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.060
CY2018	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.92
CY2016	us-gaap	Depreciation Depreciation	3300000	USD
CY2017	us-gaap	Depreciation Depreciation	2300000	USD
CY2018	us-gaap	Depreciation Depreciation	2600000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3290000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17682000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	26087000	USD
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.17
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.82
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.03
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.02
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.06
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.96
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.75
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-1584000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	6199000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-3611000	USD
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0040
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0172
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0002
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3072
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2910
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.0220
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.1984
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.1033
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.0910
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.1666
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.1953
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.0649
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0001
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0015
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0001
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0014
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0026
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0305
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0101
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0005
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17711000	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	27629000	USD
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	62600000	USD
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y11M16D
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-47000	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2018	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P7Y
CY2018Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	124531000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-1202000	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	459000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	59000	USD
CY2016	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2017	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-5000	USD
CY2018	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-2000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	0	USD
CY2018Q4	us-gaap	Goodwill Goodwill	82341000	USD
CY2018Q4	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	18000000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-61446000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-54588000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-68461000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-141541000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-77665000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-128110000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-80095000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-23077000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-59649000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-141541000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-77665000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-128110000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	569000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1335000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-29000	USD
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	943000	USD
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1101000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1583000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4259000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	24011000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	43877000	USD
CY2016	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1526000	USD
CY2017	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	9469000	USD
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	6514000	USD
CY2016	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	278000	USD
CY2017	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	544000	USD
CY2018	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	1093000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6454000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5823000	USD
CY2016	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-799000	USD
CY2017	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	733000	USD
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1932000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1171000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1784000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1609000	USD
CY2016	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	14842000	USD
CY2017	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	12203000	USD
CY2018	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	29589000	USD
CY2018	us-gaap	Indefinitelived Intangible Assets Acquired IndefinitelivedIntangibleAssetsAcquired	576500000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	132993000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	701031000	USD
CY2016	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-8276000	USD
CY2017	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-12094000	USD
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-12554000	USD
CY2016	us-gaap	Interest Paid InterestPaid	4513000	USD
CY2017	us-gaap	Interest Paid InterestPaid	6271000	USD
CY2018	us-gaap	Interest Paid InterestPaid	7773000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	6390000	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5362000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	10754000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	16117000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	452000	USD
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1431000	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	3912000	USD
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	9324000	USD
CY2018	us-gaap	Inventory Write Down InventoryWriteDown	1800000.0	USD
CY2018Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	13928000	USD
CY2018Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3216000	USD
CY2018Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2082000	USD
CY2018Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2409000	USD
CY2018Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2900000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	235216000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	768495000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	391653000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1119222000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	82048000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	166796000	USD
CY2018Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	11667000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	144971000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	141347000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	79454000	USD
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	58088000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	968000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	44218000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	131571000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	104481000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	13117000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42613000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-103566000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10063000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27641000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-142110000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-29057000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-17475000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-33738000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	1270000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-79000000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-19263000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-9520000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-50969000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-48330000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-128081000	USD
CY2016	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2017	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	0	USD
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1	5981000	USD
CY2018	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	segment
CY2016	us-gaap	Operating Expenses OperatingExpenses	214763000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	52902000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	60459000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	72745000	USD
CY2017Q4	us-gaap	Operating Expenses OperatingExpenses	72578000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	258684000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	72805000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	74317000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	101821000	USD
CY2018Q4	us-gaap	Operating Expenses OperatingExpenses	131476000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	380419000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-132058000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-26355000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12497000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-30892000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	5452000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-64292000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-16743000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5574000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-48230000	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-45138000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-115685000	USD
CY2016	us-gaap	Operating Lease Expense OperatingLeaseExpense	2200000	USD
CY2017	us-gaap	Operating Lease Expense OperatingLeaseExpense	2200000	USD
CY2018	us-gaap	Operating Lease Expense OperatingLeaseExpense	2700000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2286000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	16437000	USD
CY2016	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	386000	USD
CY2017	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	225000	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	9000	USD
CY2016	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-671000	USD
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5229000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2516000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-285000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	5454000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	-2507000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-285000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	5454000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2507000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-285000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5454000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2507000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1665000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3814000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	243000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	58000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1207000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1279000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	129000	USD
CY2016	us-gaap	Paid In Kind Interest PaidInKindInterest	6065000	USD
CY2017	us-gaap	Paid In Kind Interest PaidInKindInterest	6755000	USD
CY2018	us-gaap	Paid In Kind Interest PaidInKindInterest	7518000	USD
CY2016	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	432000	USD
CY2018	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2016	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	48892000	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	90423000	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	77163000	USD
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	8433000	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	85377000	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	81368000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	68614000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1776000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3101000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7097000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6669000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9247000	USD
CY2018Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	117916000	USD
CY2016	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	40000000	USD
CY2018	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	191634000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	174749000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	968000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2182000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10868000	USD
CY2016	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2017	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2468000	USD
CY2018	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2787000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	41220000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	20177000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8376000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12694000	USD
CY2017Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	40394000	USD
CY2018Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	67907000	USD
CY2016	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	0	USD
CY2017	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	0	USD
CY2018	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	0	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	117633000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	117456000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	171984000	USD
CY2016Q4	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	2500000	USD
CY2017Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	USD
CY2018Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-814108000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-938923000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-938900000	USD
CY2016	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	82705000	USD
CY2017Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	26442000	USD
CY2017Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	47891000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	41780000	USD
CY2017Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	57953000	USD
CY2017	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	194392000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	55981000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	68170000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	53021000	USD
CY2018Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	85833000	USD
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	264734000	USD
CY2017	us-gaap	Revenues Revenues	194392000	USD
CY2018	us-gaap	Revenues Revenues	264734000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	97130000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	121271000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	153548000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	35009000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	30559000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	33252000	USD
CY2018Q2	us-gaap	Share Price SharePrice	27.04
CY2018Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4600000	shares
CY2017	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	75191000	USD
CY2018	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	155860000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2467000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2787000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	117916000	USD
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000	USD
CY2018	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	968000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2182000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10868000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	226001000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	119583000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	156437000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	350727000	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5400000	USD
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	2800000	USD
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34044584	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39183073	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46576313	shares
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentration of credit risk</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s financial instruments that are exposed to credit risks consist primarily of cash and cash equivalents, available-for-sale marketable securities and accounts receivable. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company has not experienced any credit losses in these accounts and does not believe it is exposed to any significant credit risk on these funds. The Company’s investment policy includes guidelines on the quality of the financial institutions and financial instruments the Company is allowed to invest in, which the Company believes minimizes the exposure to concentration of credit risk.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its accounts receivable related to its product sales. The payment terms are predetermined and the Company evaluates the creditworthiness of each customer or distributor on a regular basis. The Company reserves all uninsured amounts billed directly to a patient until the time of cash receipt as collectability is not reasonably assured at the time the product is received. To date, the Company has not incurred any credit losses.</font></div></div>
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Company</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PTC Therapeutics, Inc. (the “Company” or “PTC”) is a science-led global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The Company’s ability to globally commercialize products is the foundation that drives its continued investment in a robust pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company’s strategy is to bring best-in-class therapies with differentiated clinical benefit to patients affected by rare disorders and to leverage its global commercial infrastructure to maximize value for its patients and other stakeholders.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has two products, Translarna</font><font style="font-family:inherit;font-size:8pt;">™ </font><font style="font-family:inherit;font-size:10pt;">(ataluren) and Emflaza™ (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life threatening disorder. Translarna received marketing authorization from the European Commission in August 2014 for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients aged </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;"> years and over in the </font><font style="font-family:inherit;font-size:10pt;">31</font><font style="font-family:inherit;font-size:10pt;"> member states of the European Economic Area, or EEA, subject to annual renewal and other conditions. In July 2018, the European Commission approved a label-extension request to the marketing authorization for Translarna in the EEA to include patients from two to up to five years of age. Emflaza is approved in the United States for the treatment of DMD in patients five years and older. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a pipeline of gene therapy product candidates, including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC, deficiency, or AADC deficiency. The Company is preparing a biologics license application, or BLA, for PTC-AADC for the treatment of AADC deficiency in the United States, which it anticipates submitting to the U.S. Food and Drug Administration, or FDA, in late 2019, with an anticipated commercial launch in the United States in 2020. The Company is also preparing a marketing authorization application, or MAA, for PTC-AADC for the treatment of AADC deficiency in the European Union, or EU, for submission to the European Medicines Agency, or EMA, which will follow its BLA submission to the FDA.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company holds the rights for the commercialization of Tegsedi™ (inotersen) and Waylivra™ (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean. Tegsedi has received marketing authorization in the U.S., EU and Canada for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hATTR amyloidosis. The Company filed for marketing authorization with ANVISA, the Brazilian regulatory authority, which granted priority review. It expects approval in Brazil by the end of 2019. Waylivra is currently under regulatory review in EU for the treatment of familial chylomicronemia syndrome, or FCS. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company also has a spinal muscular atrophy (“SMA”) collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., which it refers to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or SMA Foundation. Currently, its collaboration has two pivotal clinical trials ongoing to evaluate the safety and effectiveness of risdiplam (RG7916, RO7034067), the lead compound in the SMA program. Roche is preparing an NDA and a MAA for risdiplam for the treatment of SMA in the United States and the EU, respectively, which Roche anticipates submitting to the FDA and the EMA in the second half of 2019. In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the European Commission following reassessment by the EMA of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. This marketing authorization is further subject to the specific obligation to conduct and submit the results of a multi-center, randomized, double-blind, 18-month, placebo-controlled trial, followed by an 18-month open-label extension, according to an agreed protocol, in order to confirm the efficacy and safety of Translarna. The final report on the trial and open-label extension is to be submitted by the Company to the EMA by the end of the third quarter of 2021. Due to enrollment at a slower pace in certain countries than initially expected, in its February 2019 marketing authorization renewal request, the Company asked the EMA to extend the timeframe for submission of the results of Study 041 to the EMA to the end of the third quarter of 2022. The Company refers to the trial and open-label extension together as Study 041.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The marketing authorization in the EEA was last renewed in July 2018 and is effective, unless extended, through August 5, 2019. The renewal was based on the Company’s commitment to conduct Study 041 and the totality of the clinical data available from its trials and studies of Translarna for the treatment of nmDMD, including the safety and efficacy results of the Phase 2b and Phase 3 clinical trials. The primary efficacy endpoint was not achieved in either trial within the pre-specified level of statistical significance. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, the Company initiated reimbursed early access programs, or EAP programs, for Translarna for nmDMD patients in selected territories in the EEA and recorded its first sales of Translarna in the third quarter of 2014 pursuant to an EAP program. In December 2014, the Company recorded its first commercial sales in Germany. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, Translarna was available in </font><font style="font-family:inherit;font-size:10pt;">over 40</font><font style="font-family:inherit;font-size:10pt;"> countries on a commercial basis or pursuant to the EAP program. The Company expects to expand its commercial activities across the EEA pursuant to the marketing authorization granted by the EMA throughout 2019 and future years, subject to continued renewal of its marketing authorization following annual EMA reassessments and successful completion of pricing and reimbursement negotiations. Concurrently, the Company plans to continue to pursue EAP programs in select countries where those mechanisms exist, both within the EEA and in other countries that will reference the marketing authorization in the EEA.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Translarna is an investigational new drug in the United States. During the first quarter of 2017, the Company filed a New Drug Application, or NDA, over protest with the United States Food and Drug Administration, (the "FDA"), for which the FDA granted a standard review. In October 2017, the Office of Drug Evaluation I of the FDA issued a complete response letter for the NDA, stating that it was unable to approve the application in its current form. In response, the Company filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied PTC’s appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients’ muscles. The Company intends to follow the FDA’s recommendation and will collect, using newer technologies via procedures and methods that the Company designed, such dystrophin data in a new study, Study 045, which the Company initiated in the fourth quarter of 2018. The Company expects that a potential re-submission of an NDA could occur in 2020. Additionally, should a re-submission of an NDA receive accelerated approval, the Office of New Drugs stated that Study 041, which is currently enrolling, could serve as the confirmatory post-approval trial required in connection with the accelerated approval framework.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 20, 2017, the Company completed its acquisition of all rights to Emflaza, or the Transaction. Emflaza is approved in the United States for the treatment of DMD in patients five years and older. The Transaction was completed pursuant to an asset purchase agreement, dated March 15, 2017, as amended on April 20, 2017, (the "Asset Purchase Agreement"), by and between the Company and Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC), or Marathon. The Transaction was accounted for as an asset acquisition. The assets acquired by the Company in the Transaction include intellectual property rights related to Emflaza, inventories of Emflaza, and certain contractual rights related to Emflaza. The Company assumed certain liabilities and obligations in the Transaction arising out of, or relating to, the assets acquired in the Transaction. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the closing of the Transaction, the Company paid to Marathon total upfront consideration comprised of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, funded through cash on hand, and </font><font style="font-family:inherit;font-size:10pt;">6,683,598</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock. The number of shares of common stock issued at closing was determined by dividing </font><font style="font-family:inherit;font-size:10pt;">$65.0 million</font><font style="font-family:inherit;font-size:10pt;"> by the volume weighted average price per share of the Company’s common stock on the Nasdaq Stock Market for the </font><font style="font-family:inherit;font-size:10pt;">15</font><font style="font-family:inherit;font-size:10pt;"> trading-day period ending on the third trading day immediately preceding the closing. Marathon will be entitled to receive contingent payments from the Company based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over the expected commercial life of the asset, and a single </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> sales-based milestone, in each case subject to the terms and conditions of the Asset Purchase Agreement.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc., or Agilis, pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the “Merger Agreement”), by and among the Company, Agility Merger Sub, Inc., a Delaware corporation and the Company's wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the "Merger"). </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the closing of the Merger, the Company paid to Agilis equityholders total upfront consideration comprised of </font><font style="font-family:inherit;font-size:10pt;">$49.2 million</font><font style="font-family:inherit;font-size:10pt;"> in cash and </font><font style="font-family:inherit;font-size:10pt;">3,500,907</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company’s common stock (the “Closing Stock Consideration”). The Closing Stock Consideration was determined by dividing </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> by the volume-weighted average price per share of the Company’s common stock on the Nasdaq Global Select Market for the </font><font style="font-family:inherit;font-size:10pt;">10</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading-day period ending on the second trading-day immediately preceding the closing of the Merger. Agilis equityholders may become entitled to receive contingent payments from the Company based on the achievement of certain development, regulatory and net sales milestones as well as based upon a percentage of net sales of certain products. Under the Merger Agreement, the Company is required to pay </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> of the development milestone payments no later than the second anniversary of the closing of the Merger, regardless of whether the applicable milestones have been achieved.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accumulated deficit of approximately </font><font style="font-family:inherit;font-size:10pt;">$938.9 million</font><font style="font-family:inherit;font-size:10pt;">. The Company has financed its operations to date primarily through the private offering in August 2015 of </font><font style="font-family:inherit;font-size:10pt;">3.00%</font><font style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2022 (see Note 7), public offerings of common stock in February 2014, October 2014, and April 2018, its initial public offering of common stock in June 2013, private placements of its convertible preferred stock, collaborations, bank debt, convertible debt financings, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company’s product candidates. Since 2014, the Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States, and since May 2017, the Company generated revenue from net sales of Emflaza for the treatment of DMD in the United States. The Company expects that cash flows from the sales of its products, together with the Company’s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months.</font></div></div>
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, certain accruals related to the Company’s research and development expenses, stock-based compensation, valuation procedures for the convertible notes, allowance for doubtful accounts, inventory, acquired intangible assets, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</font></div></div>

Files In Submission

Name	View Source	Status
0001070081-19-000018-index-headers.html	Edgar Link	pending
0001070081-19-000018-index.html	Edgar Link	pending
0001070081-19-000018.txt	Edgar Link	pending
0001070081-19-000018-xbrl.zip	Edgar Link	pending
exhibit23112312018.htm	Edgar Link	pending
exhibit31112312018.htm	Edgar Link	pending
exhibit31212312018.htm	Edgar Link	pending
exhibit32112312018.htm	Edgar Link	pending
exhibit32212312018.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipelinechart.jpg	Edgar Link	pending
ptct-20181231.xml	Edgar Link	completed
ptct-20181231.xsd	Edgar Link	pending
ptct-20181231_cal.xml	Edgar Link	unprocessable
ptct-20181231_def.xml	Edgar Link	unprocessable
ptct-20181231_lab.xml	Edgar Link	unprocessable
ptct-20181231_pre.xml	Edgar Link	unprocessable
ptct1231201810-k.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTCT
PTC THERAPEUTICS, INC. Stock $ptct

2019 Q1 Form 10-K Financial Statement

#000107008119000018 Filed on March 01, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT PTC THERAPEUTICS, INC. Stock $ptct

2019 Q1 Form 10-K Financial Statement

#000107008119000018 Filed on March 01, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTCT
PTC THERAPEUTICS, INC. Stock $ptct